Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Thyroid Gland Carcinoma”

115 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 115 results

Very early researchLooking for participantsNCT06898437
What this trial is testing

Study of 177Lu-LNC1004 Injection in FAP-positive Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Radioiodine Refractory Differentiated Thyroid Cancer
Peking Union Medical College Hospital 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT02867592
What this trial is testing

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

Who this might be right for
Adrenal Cortical CarcinomaAlveolar Soft Part SarcomaCentral Nervous System Neoplasm+41 more
National Cancer Institute (NCI) 109
Not applicableStudy completedNCT02303444
What this trial is testing

An Observational Study in Differentiated Thyroid Cancer Which is Radioactive Iodine (RAI) Refractory to Assess the Use of Multikinase Inhibitors

Who this might be right for
Thyroid Neoplasms
Bayer 667
Not applicableNo Longer AvailableNCT05225259
What this trial is testing

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did Not Respond/is no Longer Responding to Treatment With a Type of Drug Called a RET Inhibitor

Who this might be right for
Carcinoma, Non-Small-Cell LungThyroid Neoplasms
Eli Lilly and Company
Testing effectiveness (Phase 2)Study completedNCT00381641
What this trial is testing

Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery

Who this might be right for
Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaRefractory Thyroid Gland Carcinoma+16 more
National Cancer Institute (NCI) 63
Testing effectiveness (Phase 2)Study completedNCT01811212
What this trial is testing

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Who this might be right for
Poorly Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland CarcinomaStage I Thyroid Gland Follicular Carcinoma+13 more
National Cancer Institute (NCI) 25
Testing effectiveness (Phase 2)Active Not RecruitingNCT04544111
What this trial is testing

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerThyroid Cancer, FollicularPapillary Thyroid Cancer+4 more
Memorial Sloan Kettering Cancer Center 19
Not applicableStudy completedNCT03191643
What this trial is testing

PET-guided External Beam Radiotherapy in Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
IRCCS Azienda Ospedaliero-Universitaria di Bologna 16
Early research (Phase 1)Active Not RecruitingNCT04420754
What this trial is testing

Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer

Who this might be right for
Anaplastic Thyroid CancerRelapsed/Refractory Poorly Differentiated Thyroid Cancer
AffyImmune Therapeutics, Inc. 70
Not applicableLooking for participantsNCT06443866
What this trial is testing

I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer

Who this might be right for
Thyroid CancerRAI-Refractory Thyroid Cancer
Miami Cancer Research Center, Inc. 50
Large-scale testing (Phase 3)Ended earlyNCT03602495
What this trial is testing

Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 204
Testing effectiveness (Phase 2)Study completedNCT01813136
What this trial is testing

Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma

Who this might be right for
Thyroid Carcinoma
Centre Leon Berard 168
Testing effectiveness (Phase 2)Active Not RecruitingNCT02465060
What this trial is testing

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmBladder Carcinoma+49 more
National Cancer Institute (NCI) 6,452
Testing effectiveness (Phase 2)Looking for participantsNCT06970353
What this trial is testing

Phase II Trial of Tunlametinib in NRAS-Mutant Advanced Thyroid Cancer

Who this might be right for
Radioactive Iodine-refractory, Differentiated Thyroid Cancer With NRAS MutationAdvanced PDTC or ATC With NRAS Mutation
Fudan University 40
Early research (Phase 1)Ended earlyNCT00002947
What this trial is testing

Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

Who this might be right for
Brain and Central Nervous System TumorsChildhood Langerhans Cell HistiocytosisGastrointestinal Carcinoid Tumor+9 more
Yale University 35
Testing effectiveness (Phase 2)Study completedNCT00936858
What this trial is testing

RAD001 for Patients With Radioiodine Refractory Thyroid Cancer

Who this might be right for
Thyroid Cancer
Dana-Farber Cancer Institute 50
Testing effectiveness (Phase 2)Looking for participantsNCT06359847
What this trial is testing

Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited 60
Large-scale testing (Phase 3)Active Not RecruitingNCT04940052
What this trial is testing

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Who this might be right for
Differentiated Thyroid Cancer (DTC)
Novartis Pharmaceuticals 153
Testing effectiveness (Phase 2)Looking for participantsNCT05668962
What this trial is testing

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Who this might be right for
Thyroid CancerThyroid CarcinomaMetastatic Thyroid Cancer+3 more
Massachusetts General Hospital 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT02143726
What this trial is testing

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Advanced, Radioactive Iodine Refractory Hurthle Cell Thyroid Cancer

Who this might be right for
Refractory Hurthle Cell Thyroid Cancer
Alliance for Clinical Trials in Oncology 35
Load More Results